BNP Paribas Financial Markets Takes Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

BNP Paribas Financial Markets acquired a new stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 86,809 shares of the company's stock, valued at approximately $647,000. BNP Paribas Financial Markets owned approximately 0.13% of EyePoint Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. RA Capital Management L.P. acquired a new position in EyePoint Pharmaceuticals in the 4th quarter worth $23,705,000. TCG Crossover Management LLC lifted its position in shares of EyePoint Pharmaceuticals by 287.3% in the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock worth $26,614,000 after purchasing an additional 2,650,000 shares in the last quarter. Adage Capital Partners GP L.L.C. grew its position in EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock valued at $42,838,000 after purchasing an additional 1,958,580 shares in the last quarter. Federated Hermes Inc. lifted its position in EyePoint Pharmaceuticals by 92.7% during the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock worth $27,620,000 after buying an additional 1,783,765 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 24.8% in the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after acquiring an additional 755,045 shares in the last quarter. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT traded down $0.13 during midday trading on Thursday, reaching $6.91. The company's stock had a trading volume of 196,632 shares, compared to its average volume of 821,770. The company has a market cap of $475.62 million, a P/E ratio of -3.46 and a beta of 1.58. The business's 50 day moving average price is $5.83 and its two-hundred day moving average price is $7.04. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.65). The company had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%. Sell-side analysts forecast that EyePoint Pharmaceuticals, Inc. will post -2.13 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have weighed in on EYPT. HC Wainwright reaffirmed a "buy" rating and set a $22.00 price target on shares of EyePoint Pharmaceuticals in a research report on Thursday, March 6th. Wall Street Zen raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Mizuho decreased their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating on the stock in a report on Friday, May 16th. Finally, Chardan Capital reduced their target price on shares of EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $25.38.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.